1. Makide K, Kitamura H, Sato Y, Okutani M, Aoki J. Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins Other Lipid Mediat. 89:135–9, 2009.
2. Makide K, Uwamizu A, Shinjo Y, Ishiguro J, Okutani M, Inoue A, et al. Novel lysophospholipid receptors: their structure and function. J Lipid Res. 55:1986–95, 2014.
3. Metz SA. Lysophosphatidylinositol, but not lysophosphatidic acid, stimulates insulin release. A possible role for phospholipase A2 but not de novo synthesis of lysophospholipid in pancreatic islet function. Biochem Biophys Res Commun. 138:720–727, 1986.
4. Kurano M, Kano K, Hara M, Tsukamoto K, Aoki J, Yatomi Y. Regulation of plasma glycero-lysophospholipid levels by lipoprotein metabolism. Biochem J. 476:3565–81, 2019.
5. Okita M, Gaudette DC, Mills GB, Holub BJ. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. Int J Cancer. 71:31–4, 1997.
6. Sun J, Shannon M, Ando Y, Schnackenberg LK, Khan NA, Portilla D, et al. Serum metabolomic profiles from patients with acute kidney injury: a pilot study. J Chromatogr B Anal Technol Biomed Life Sci. 893–894:107– 13, 2012.
7. Tiwari-Heckler S, Gan-Schreier H, Stremmel W, Chamulitrat W, Pathil A. Circulating phospholipid patterns in NAFLD patients associated with a combination of metabolic risk factors. Nutrients. 10:649, 2018.
8. Heimerl S, Fischer M, Baessler A, Liebisch G, Sigruener A, Wallner S, et al. Alterations of plasma lysophosphatidylcholine species in obesity and weight loss. PLoS One. 9:1–7, 2014.
9. Kishimoto T, Soda Y, Matsuyama Y, Mizuno K. An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. Clin Biochem. 35:411–6, 2002.
10. Vuong TD, De Kimpe S, De Roos R, Rabelink TJ, Koomans HA, Joles JA. Albumin restores lysophosphatidylcholine-induced inhibition of vasodilation in rat aorta. Kidney Int. 60:1088–96, 2001.
11. Perrin-Cocon L, Agaugué S, Coutant F, Saint-Mézard P, Guironnet-Paquet A, Nicolas JF, et al. Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses. Vaccine. 24:1254–63, 2006.
12. Lehmann R, Franken H, Dammeier S, Rosenbaum L, Kantartzis K, Peter A, et al. Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care. 36:2331–8, 2013.
13. Nishina A, Kimura H, Sekiguchi A, Fukumoto RH, Nakajima S, Furukawa S. Lysophosphatidylethanolamine in Grifola frondosa as a neurotrophic activator via activation of MAPK. J Lipid Res. 47:1434–43, 2006.
14. Park KS, Lee HY, Lee SY, Kim MK, Kim SD, Kim JM, et al. Lysophosphatidylethanolamine stimulates chemotactic migration and cellular invasion in SK-OV3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor. FEBS Lett. 581:4411–6, 2007.
15. Ren C, Liu J, Zhou J, Liang H, Wang Y, Sun Y, et al. Lipidomic analysis of serum samples from migraine patients. Lipids Health Dis. 17:1–9, 2018.
16. Kihara Y, Mizuno H, Chun J. Lysophospholipid receptors in drug discovery. Exp Cell Res. 333:171–7, 2015.
17. Gowda SGB, Gao ZJ, Chen Z, Abe T, Hori S, Fukiya S, et al. Untargeted lipidomic analysis of plasma from high-fat diet-induced obese rats using UHPLC-linear trap quadrupole-OrbitrapMS. Anal Sci. 36:821–8, 2020.
18. Furukawa T, Fuda H, Miyanaga S, Watanabe C, Chiba H, Hui SP. Rapid tin-mediated access to a lysophosphatidylethanolamine (LPE) library: application to positional LC/MS analysis for hepatic LPEs in nonalcoholic steatohepatitis model mice. Chem Phys Lipids. 200:133–8, 2016.
19. Koistinen KM, Suoniemi M, Simolin H, Ekroos K. Quantitative lysophospholipidomics in human plasma and skin by LC-MS/MS. Anal Bioanal Chem. 407:5091–9, 2015.
20. Ahmed A,Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 13:2062–70, 2015.
21. Siddabasave SG, Fuda H, Yamamoto Y, Chiba H, Hui SP. Asimple and efficient method for synthesis of sn-glycerophosphoethanolamine. Lipids. 55:395–401, 2020.
22. Hui SP, Murai T, Yoshimura T, Chiba H, Kurosawa T. Simple Chemical Syntheses of TAG Monohydroperoxides. Lipids. 38:1287–1292, 2003.
23. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 37:911–7, 1959.
24. Fujii Y, Nouso K, Matsushita H, Kariyama K, Sakurai T, Takahashi Y, et al. Low-density lipoprotein (LDL)-triglyceride and its ratio to LDLcholesterol as diagnostic biomarkers for nonalcoholic steatohepatitis. J Appl Lab Med. 1–10, 2020.
25. Chen Z, Wu Y, Nagano M, Ueshiba K, Furukawa E, Yamamoto Y, et al. Lipidomic profiling of dairy cattle oocytes by high performance liquid chromatography-high resolution tandem mass spectrometry for developmental competence markers. Theriogenology. 144:56–66, 2020.
26. Sud M, Fahy E, Cotter D, Brown A, Dennis EA, Glass CK, et al. LMSD: LIPID MAPS structure database. Nucleic Acids Res. 35:527–32, 2007.
27. Yamamoto Y, Furukawa T, Takeda S, Kashida H, Chiba H, Hui SP. Examining the effect of regioisomerism on the physico-chemical properties of lysophosphatidylethanolamine-containing liposomes using fluoro probes. Chem Phys Lipids. 216:9–16, 2018.
28. Tanaka N, Matsubara T, Krausz KW, Patterson AD, Gonzalez FJ. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology. 56:118–29, 2012.
29. Law SH, Chan ML, Marathe GK, Parveen F, Chen CH, Ke LY. An updated review of lysophosphatidylcholine metabolism in human diseases. Int J Mol Sci. 20:1–24, 2019.
30. Hishikawa D, Shindou H, Kobayashi S, Nakanishi H, Taguchi R, Shimizu T. Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversity. Proc Natl Acad Sci U S A. 105:2830– 5, 2008.
31. Gotoh N, Noguchi Y, Ishihara A, Yamaguchi K, Mizobe H, Nagai T, et al. Highly unsaturated fatty acid might act as an antioxidant in emulsion system oxidized by azo compound. J Oleo Sci. 59: 631–9, 2010.
32. Patel D, Witt SN. Ethanolamine and phosphatidylethanolamine: partners in health and disease. Oxidative Med Cell Longev. 2017. https://doi.org/10.1155/2017/4829180.
33. Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, et al. 2-Hydroxyglutarate-mediated autophagy of the endoplasmic reticulumleads to an unusual downregulation of phospholipid biosynthesis in mutant Idh1 gliomas. Cancer Res. 78:2290– 304, 2018.
34. Lebeaupin C, Vallée D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of nonalcoholic fatty liver disease. J Hepatol. 69:927–47, 2018.
35. Wang A, Loo R, Chen Z, Dennis EA. Regiospecificity and catalytic triad of lysophospholipase I. J Biol Chem. 272:22030–22036, 1997.
36. Shindou H, Hishikawa D, Harayama T, Eto M, Shimizu T. Generation of membrane diversity by lysophospholipid acyltransferases. J Biochem. 154:21–28, 2013.
37. Kim HJ, Kim JH, Noh S, Hur HJ, Sung MJ, Hwang JT, Park JH, Yang HJ, Kim MS, Kwon DY, Yoon SH. Metabolomic analysis of livers and serum from high-fat diet induced obese mice. J Proteome Res. 10:722–731, 2011.
38. Corrêa R, Silva LFF, Ribeiro DJS, Almeida R das N, Santos I de O, Corrêa LH, de Sant’Ana LP, Assunção LS, Bozza PT, Magalhães KG. Lysophosphatidylcholine Induces NLRP3 Inflammasome-Mediated Foam Cell Formation and Pyroptosis in Human Monocytes and Endothelial Cells. Front Immunol. 10:1–15, 2020.
39. Kakisaka K, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, Werneburg NW, Mott JL, Gores GJ. Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol - Gastrointest Liver Physiol. 302:77–84, 2012.
40. Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, BirnerGruenberger R, Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A, Zechner R. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science. (80- ) 306:1383–1386, 2004.
41. Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem. 279:48968–48975, 2004.
42. Turpin SM, Hoy AJ, Brown RD, Garcia Rudaz C, Honeyman J, Matzaris M, Watt MJ. Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. Diabetologia. 54:146– 156, 2011.
43. Antal O, Péter M, Hackler L, Mán I, Szebeni G, Ayaydin F, Hideghéty K, Vigh L, Kitajka K, Balogh G, Puskás LG. Lipidomic analysis reveals a radiosensitizing role of gamma-linolenic acid in glioma cells. Biochim Biophys Acta - Mol Cell Biol Lipids. 1851:1271–1282, 2015.
44. Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3KAKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci. 117:202017152, 2020.
45. Vida M, Gavito AL, Pavoń FJ, Bautista D, Serrano A, Suarez J, Arrabal S, Decara J, Romero-Cuevas M, De Fonseca FR, Baixeras E. Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6- deficient mice. DMM Dis Model Mech. 8:721–731, 2015.
論文の公開元へ
